 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Efficacy of TKI combined with anti-PD-1 therapy for early postoperative recurrence of hepatocellular carcinoma

Front Oncol: Efficacy of TKI combined with anti-PD-1 therapy for early postoperative recurrence of hepatocellular carcinoma

 Last Update: 2022-04-15
 Source: Internet
 Author: User

Tags

reciprocal 1 2

5 6 models

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Frontiers in Oncology published a research result from a team from Jinling Hospital of Nanjing University, mainly to evaluate the efficacy of TKI combined with anti-PD-1 therapy for early postoperative recurrence of hepatocellular carcinoma (HCC) and related influencing factors

Mainly to evaluate the efficacy of TKI combined with anti-PD-1 therapy and related influencing factors for early postoperative recurrence of hepatocellular carcinoma (HCC)

According to the time of recurrence and metastasis, patients were divided into early (≤2 years) and late (>2 years)

This study finally included 58 patients with liver cancer who underwent radical resection, including 39 in the TKIs group and 19 in the TKIs + ICIs combined treatment group

The efficacy evaluation of TKIs group: PD 7 cases, PR 9 cases, SD 23 cases

The median PFS in the TKIs treatment group and the TKIs + ICIs combination treatment group was 6.

Univariate COX regression analysis showed that the OS of patients with ascites was worse than that of patients without ascites, HR (95% CI): 2.

In conclusion, the study shows that the combined therapy of TKIs + ICIs is better than TKIs monotherapy in patients with early recurrent hepatocellular carcinoma, and the prognosis of patients with ascites, HBV DNA positive and high AFP expression is poor.

Studies have shown that TKIs + ICIs combination therapy is more effective than TKIs monotherapy in patients with early recurrent hepatocellular carcinoma, and patients with ascites, positive HBV DNA, and high AFP expression have a poorer prognosis.

Original source:

Li Z, Han N, Ren X, Zhang Y and Chu X (2022) Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study.

Li Z, Han N, Ren X, Zhang Y and Chu X (2022) Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study.
Front.
Oncol.
12:833884.
doi : 10.
3389/fonc.
2022.
833884.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.